These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

699 related articles for article (PubMed ID: 27349252)

  • 61. GnRH Agonist and hCG (Dual Trigger) Versus hCG Trigger for Final Oocyte Maturation in Expected Normal Responders With a High Immature Oocyte Rate: Study Protocol for a Randomized, Superiority, Parallel Group, Controlled Trial.
    Yan MH; Cao JX; Hou JW; Jiang WJ; Wang DD; Sun ZG; Song JY
    Front Endocrinol (Lausanne); 2022; 13():831859. PubMed ID: 35418945
    [TBL] [Abstract][Full Text] [Related]  

  • 62. Ovarian hyperstimulation syndrome: a clinical report on 4894 consecutive ART treatment cycles.
    Sousa M; Cunha M; Teixeira da Silva J; Oliveira C; Silva J; Viana P; Barros A
    Reprod Biol Endocrinol; 2015 Jun; 13():66. PubMed ID: 26100393
    [TBL] [Abstract][Full Text] [Related]  

  • 63. Gonadotropin-releasing hormone agonist trigger in oocyte donors co-treated with a gonadotropin-releasing hormone antagonist: a dose-finding study.
    Vuong TN; Ho MT; Ha TD; Phung HT; Huynh GB; Humaidan P
    Fertil Steril; 2016 Feb; 105(2):356-63. PubMed ID: 26523330
    [TBL] [Abstract][Full Text] [Related]  

  • 64. Co-administration of GnRH-agonist and hCG, for final oocyte maturation (double trigger), in patients with low proportion of mature oocytes.
    Zilberberg E; Haas J; Dar S; Kedem A; Machtinger R; Orvieto R
    Gynecol Endocrinol; 2015 Feb; 31(2):145-7. PubMed ID: 25385007
    [TBL] [Abstract][Full Text] [Related]  

  • 65. Gonadotropin-releasing hormone agonist (GnRHa) trigger - State of the art.
    Dosouto C; Haahr T; Humaidan P
    Reprod Biol; 2017 Mar; 17(1):1-8. PubMed ID: 28215488
    [TBL] [Abstract][Full Text] [Related]  

  • 66. Combined GnRH-agonist and human chorionic gonadotropin trigger improves ICSI cycle outcomes in patients with history of poor fertilization.
    Elias RT; Pereira N; Artusa L; Kelly AG; Pasternak M; Lekovich JP; Palermo GD; Rosenwaks Z
    J Assist Reprod Genet; 2017 Jun; 34(6):781-788. PubMed ID: 28444614
    [TBL] [Abstract][Full Text] [Related]  

  • 67. GnRH agonist to induce oocyte maturation during IVF in patients at high risk of OHSS.
    Engmann L; Siano L; Schmidt D; Nulsen J; Maier D; Benadiva C
    Reprod Biomed Online; 2006 Nov; 13(5):639-44. PubMed ID: 17169172
    [TBL] [Abstract][Full Text] [Related]  

  • 68. Daily low-dose hCG stimulation during the luteal phase combined with GnRHa triggered IVF cycles without exogenous progesterone: a proof of concept trial.
    Andersen CY; Elbaek HO; Alsbjerg B; Laursen RJ; Povlsen BB; Thomsen L; Humaidan P
    Hum Reprod; 2015 Oct; 30(10):2387-95. PubMed ID: 26209535
    [TBL] [Abstract][Full Text] [Related]  

  • 69. Intranasal gonadotropin-releasing hormone agonist (GnRHa) for luteal-phase support following GnRHa triggering, a novel approach to avoid ovarian hyperstimulation syndrome in high responders.
    Bar-Hava I; Mizrachi Y; Karfunkel-Doron D; Omer Y; Sheena L; Carmon N; Ben-David G
    Fertil Steril; 2016 Aug; 106(2):330-3. PubMed ID: 27114332
    [TBL] [Abstract][Full Text] [Related]  

  • 70. Dual Triggering With Gonadotropin-Releasing Hormone Agonist and Standard Dose Human Chorionic Gonadotropin in Patients With a High Immature Oocyte Rate.
    Fabris AM; Cruz M; Legidos V; Iglesias C; Muñoz M; García-Velasco JA
    Reprod Sci; 2017 Aug; 24(8):1221-1225. PubMed ID: 28715965
    [TBL] [Abstract][Full Text] [Related]  

  • 71. Incidence and prediction of ovarian hyperstimulation syndrome in women undergoing gonadotropin-releasing hormone antagonist in vitro fertilization cycles.
    Papanikolaou EG; Pozzobon C; Kolibianakis EM; Camus M; Tournaye H; Fatemi HM; Van Steirteghem A; Devroey P
    Fertil Steril; 2006 Jan; 85(1):112-20. PubMed ID: 16412740
    [TBL] [Abstract][Full Text] [Related]  

  • 72. Dual trigger improves the pregnancy rate in fresh in vitro fertilization (IVF) cycles compared with the human chorionic gonadotropin (hCG) trigger: a systematic review and meta-analysis of randomized trials.
    Hsia LH; Lee TH; Lin YH; Huang YY; Chang HJ; Liu YL
    J Assist Reprod Genet; 2023 Sep; 40(9):2063-2077. PubMed ID: 37466846
    [TBL] [Abstract][Full Text] [Related]  

  • 73. Co-administration of GnRH-agonist and hCG (double trigger) for final oocyte maturation increases the number of top-quality embryos in patients undergoing IVF/ICSI cycles.
    Tu B; Zhang H; Chen L; Yang R; Liu P; Li R; Qiao J
    J Ovarian Res; 2024 Jul; 17(1):137. PubMed ID: 38961417
    [TBL] [Abstract][Full Text] [Related]  

  • 74. Serum inhibin A, VEGF and TNFalpha levels after triggering oocyte maturation with GnRH agonist compared with HCG in women with polycystic ovaries undergoing IVF treatment: a prospective randomized trial.
    Babayof R; Margalioth EJ; Huleihel M; Amash A; Zylber-Haran E; Gal M; Brooks B; Mimoni T; Eldar-Geva T
    Hum Reprod; 2006 May; 21(5):1260-5. PubMed ID: 16439507
    [TBL] [Abstract][Full Text] [Related]  

  • 75. Elective cryopreservation of all pronuclear oocytes after GnRH agonist triggering of final oocyte maturation in patients at risk of developing OHSS: a prospective, observational proof-of-concept study.
    Griesinger G; von Otte S; Schroer A; Ludwig AK; Diedrich K; Al-Hasani S; Schultze-Mosgau A
    Hum Reprod; 2007 May; 22(5):1348-52. PubMed ID: 17303632
    [TBL] [Abstract][Full Text] [Related]  

  • 76. Is oocyte maturation rate associated with triptorelin dose used for triggering final oocyte maturation in patients at high risk for severe ovarian hyperstimulation syndrome?
    Lainas GT; Lainas TG; Sfontouris IA; Chatzimeletiou K; Venetis CA; Bosdou JK; Tarlatzis BC; Grimbizis GF; Kolibianakis EM
    Hum Reprod; 2019 Sep; 34(9):1770-1777. PubMed ID: 31384921
    [TBL] [Abstract][Full Text] [Related]  

  • 77. GnRH agonist and hCG (dual trigger) versus hCG trigger for final follicular maturation: a double-blinded, randomized controlled study.
    Haas J; Bassil R; Samara N; Zilberberg E; Mehta C; Orvieto R; Casper RF
    Hum Reprod; 2020 Jul; 35(7):1648-1654. PubMed ID: 32563188
    [TBL] [Abstract][Full Text] [Related]  

  • 78. Ovulation induction and luteal support with GnRH agonist in patients at high risk for hyperstimulation syndrome.
    Fusi FM; Arnoldi M; Bosisio C; Lombardo G; Ferrario M; Zanga L; Galimberti A; Capitanio E
    Gynecol Endocrinol; 2015; 31(9):693-7. PubMed ID: 26527503
    [TBL] [Abstract][Full Text] [Related]  

  • 79. Comparison of "triggers" using leuprolide acetate alone or in combination with low-dose human chorionic gonadotropin.
    Shapiro BS; Daneshmand ST; Garner FC; Aguirre M; Hudson C
    Fertil Steril; 2011 Jun; 95(8):2715-7. PubMed ID: 21550042
    [TBL] [Abstract][Full Text] [Related]  

  • 80. Human recombinant luteinizing hormone is as effective as, but safer than, urinary human chorionic gonadotropin in inducing final follicular maturation and ovulation in in vitro fertilization procedures: results of a multicenter double-blind study.
    European Recombinant LH Study Group
    J Clin Endocrinol Metab; 2001 Jun; 86(6):2607-18. PubMed ID: 11397861
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 35.